155 related articles for article (PubMed ID: 32745818)
1. Identifying representative kinases for inhibitor evaluation via systematic analysis of compound-based target relationships.
Laufkötter O; Laufer S; Bajorath J
Eur J Med Chem; 2020 Oct; 204():112641. PubMed ID: 32745818
[TBL] [Abstract][Full Text] [Related]
2. Systematic computational identification of promiscuity cliff pathways formed by inhibitors of the human kinome.
Miljković F; Vogt M; Bajorath J
J Comput Aided Mol Des; 2019 Jun; 33(6):559-572. PubMed ID: 30915709
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Data-Driven Assessment of Non-Kinase Targets of Inhibitors of the Human Kinome.
Mobasher M; Vogt M; Xerxa E; Bajorath J
Biomolecules; 2024 Feb; 14(3):. PubMed ID: 38540679
[TBL] [Abstract][Full Text] [Related]
4. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Gao Y; Davies SP; Augustin M; Woodward A; Patel UA; Kovelman R; Harvey KJ
Biochem J; 2013 Apr; 451(2):313-28. PubMed ID: 23398362
[TBL] [Abstract][Full Text] [Related]
5. Minimal screening requirements for identifying highly promiscuous kinase inhibitors.
Bajorath J
Future Med Chem; 2021 Jul; 13(13):1083-1085. PubMed ID: 33998280
[No Abstract] [Full Text] [Related]
6. Systematic assessment of structure-promiscuity relationships between different types of kinase inhibitors.
Hu H; Bajorath J
Bioorg Med Chem; 2021 Jul; 41():116226. PubMed ID: 34082305
[TBL] [Abstract][Full Text] [Related]
7. Data structures for computational compound promiscuity analysis and exemplary applications to inhibitors of the human kinome.
Miljković F; Bajorath J
J Comput Aided Mol Des; 2020 Jan; 34(1):1-10. PubMed ID: 31792884
[TBL] [Abstract][Full Text] [Related]
8. Promiscuity analysis of a kinase panel screen with designated p38 alpha inhibitors.
González-Medina M; Miljković F; Haase GS; Drueckes P; Trappe J; Laufer S; Bajorath J
Eur J Med Chem; 2020 Feb; 187():112004. PubMed ID: 31881458
[TBL] [Abstract][Full Text] [Related]
9. Current compound coverage of the kinome.
Hu Y; Furtmann N; Bajorath J
J Med Chem; 2015 Jan; 58(1):30-40. PubMed ID: 25051177
[TBL] [Abstract][Full Text] [Related]
10. Kinase inhibitor data set for systematic analysis of representative kinases across the human kinome.
Laufkötter O; Laufer S; Bajorath J
Data Brief; 2020 Oct; 32():106189. PubMed ID: 32904416
[TBL] [Abstract][Full Text] [Related]
11. Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome.
Rao S; Gurbani D; Du G; Everley RA; Browne CM; Chaikuad A; Tan L; Schröder M; Gondi S; Ficarro SB; Sim T; Kim ND; Berberich MJ; Knapp S; Marto JA; Westover KD; Sorger PK; Gray NS
Cell Chem Biol; 2019 Jun; 26(6):818-829.e9. PubMed ID: 30982749
[TBL] [Abstract][Full Text] [Related]
12. Systematic identification of the druggable interactions between human protein kinases and naturally occurring compounds in endometriosis.
Jiang L; Tang C; Rao J; Xue Q; Wu H; Wu D; Zhang A; Chen L; Shen Z; Lei L
Comput Biol Chem; 2017 Dec; 71():136-143. PubMed ID: 29096379
[TBL] [Abstract][Full Text] [Related]
13. Kinome-Wide Profiling Prediction of Small Molecules.
Sorgenfrei FA; Fulle S; Merget B
ChemMedChem; 2018 Mar; 13(6):495-499. PubMed ID: 28544552
[TBL] [Abstract][Full Text] [Related]
14. Systematic Profiling and Evaluation of Structure-based Kinase-Inhibitor Interactome in Cervical Cancer by Integrating In Silico Analyses and In Vitro Assays at Molecular and Cellular Levels.
Zhu LX; Liu Q; Hua YF; Yang N; Zhang XG; Ding X
Comput Biol Chem; 2019 Jun; 80():324-332. PubMed ID: 31078911
[TBL] [Abstract][Full Text] [Related]
15. Exploring structure-promiscuity relationships using dual-site promiscuity cliffs and corresponding single-site analogs.
Hu H; Bajorath J
Bioorg Med Chem; 2020 Jan; 28(1):115238. PubMed ID: 31818631
[TBL] [Abstract][Full Text] [Related]
16. Chemical genomic and proteomic methods for determining kinase inhibitor selectivity.
Krishnamurty R; Maly DJ
Comb Chem High Throughput Screen; 2007 Sep; 10(8):652-66. PubMed ID: 18045078
[TBL] [Abstract][Full Text] [Related]
17. Assessing Scaffold Diversity of Kinase Inhibitors Using Alternative Scaffold Concepts and Estimating the Scaffold Hopping Potential for Different Kinases.
Dimova D; Bajorath J
Molecules; 2017 May; 22(5):. PubMed ID: 28467353
[TBL] [Abstract][Full Text] [Related]
18. Mapping of inhibitors and activity data to the human kinome and exploring promiscuity from a ligand and target perspective.
Hu Y; Kunimoto R; Bajorath J
Chem Biol Drug Des; 2017 Jun; 89(6):834-845. PubMed ID: 27933727
[TBL] [Abstract][Full Text] [Related]
19. Extending kinome coverage by analysis of kinase inhibitor broad profiling data.
Jacoby E; Tresadern G; Bembenek S; Wroblowski B; Buyck C; Neefs JM; Rassokhin D; Poncelet A; Hunt J; van Vlijmen H
Drug Discov Today; 2015 Jun; 20(6):652-8. PubMed ID: 25596550
[TBL] [Abstract][Full Text] [Related]
20. What general conclusions can we draw from kinase profiling data sets?
Sutherland JJ; Gao C; Cahya S; Vieth M
Biochim Biophys Acta; 2013 Jul; 1834(7):1425-33. PubMed ID: 23333421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
